Comparison of Low- Versus High-Level Angle Kappa Compensation Strategies in SMILE Using the VisuMax 800: A Randomized Clinical Trial
Key facts
- Who runs it
- Zhongshan Ophthalmic Center, Sun Yat-sen University
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 100 people, planned
- Started
- 8 Apr 2026
- Expected to end
- 30 May 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Apply high compensation to the Kappa angle.
- Apply low compensation to the Kappa angle.
- Record updated
- 7 July 2026
Who can take part
- Age
- 18 years to 40 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Age range: 18 - 40 years old. Patients with stable refractive status for >= 1 year, having myopia or myopic astigmatism, with refractive power within the range of SMILE procedure
- Normal corneal morphology and corneal thickness meeting the surgical requirements
- Best corrected visual acuity (CDVA) before surgery >= 1.0
- The kappa angle-related offset coordinates (x, y) obtained before surgery, with the absolute value of either |x| or |yl| of any eye >= 0.20mm
- Voluntary to undergo SMILE surgery on the VISUMAX800 platform, understanding the random grouping scheme and signing the informed consent form
Who cannot take part
- History of prior ocular surgery, significant ocular trauma, or presence of corneal or ocular diseases that may affect the safety of refractive surgery
- Severe systemic diseases that may affect ocular healing or surgical safety
- Females who are pregnant or lactating
- Inability to cooperate as required to complete the procedure or follow-up visits
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 40 years old?
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to compare two intraoperative kappa-angle compensation strategies during small incision lenticule extraction (SMILE) using the VisuMax 800 platform in patients with relatively large kappa-angle offsets.
Read full original descriptionShow less
Angle kappa represents the difference between the visual axis and the pupil center. In patients with a large offset, pupil-centered treatment may lead to decentration of the optical zone, which can induce higher-order aberrations and affect postoperative visual quality. The VisuMax 800 system allows intraoperative adjustment of the treatment center based on the measured offset, making different compensation strategies possible.
The main questions this study aims to answer are:
Does low kappa-angle compensation (50%) result in lower postoperative higher-order aberrations than high compensation (100%)? Does the compensation strategy influence visual acuity, refractive outcomes, contrast sensitivity, and subjective visual quality after SMILE? Are the measurements obtained from different diagnostic devices consistent when evaluating kappa-related parameters?
Researchers will compare SMILE with low compensation to SMILE with high compensation to determine which strategy provides better optical quality and visual performance.
Participants will:
Undergo SMILE surgery using either low or high kappa-angle compensation Complete scheduled postoperative examinations at 1 month, 3 months, and 6 months Receive measurements of visual acuity, refraction, higher-order aberrations, contrast sensitivity, and patient-reported visual outcomes Be monitored for safety outcomes and adverse events during follow-up
The 2 groups in the trial
- Low-Level compensation groupExisting treatment, for comparison
Subjects underwent SMILE surgery on the VisuMax 800 platform. Preoperatively, decentration coordinates (x, y) were measured. While preserving the directional sign, the absolute value of the planned compensation was set to 50% of the measured decentration; the values were then rounded to the nearest increment permitted by the device input precision and entered into the system. All other surgical procedures, as well as postoperative medication and follow-up protocols, were performed according to a standardized regimen.
Treatment: Apply low compensation to the Kappa angle.
- High-Level compensation groupTreatment being tested
Subjects also underwent SMILE surgery on the VisuMax 800 platform. Decentration coordinates (x, y) were measured, and the theoretical compensation was set at 100% of the measured decentration. While preserving the directional sign, the measured values were entered directly into the device without any additional adjustment. Except for the different compensation strategy, all other surgical procedures and postoperative management were identical to those of the low-compensation group.
Treatment: Apply high compensation to the Kappa angle.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Criteria questions
- Built from NCT07512102, who can take part
- Record updated
- 7 July 2026